Finerenone in Type 1 Diabetes and Chronic Kidney Disease - PubMed

3 hours ago

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, was tested in adults with type 1 diabetes and chronic kidney disease (CKD).
The study involved 242 participants with type 1 diabetes, CKD, and albuminuria, all receiving ACE inhibitors or angiotensin-receptor blockers.
Participants were randomized to receive finerenone (10 or 20 mg/day) or placebo, with the primary outcome being the relative change in the urinary albumin-to-creatinine ratio over 6 months.
Results showed a 34% reduction in the urinary albumin-to-creatinine ratio with finerenone compared to a 12% reduction with placebo, indicating a significant 25% greater reduction with finerenone.
Hyperkalemia was the most common adverse event, occurring in 10.1% of finerenone recipients versus 3.3% with placebo, leading to discontinuation in 1.7% of finerenone users.
The estimated glomerular filtration rate (eGFR) declined more with finerenone (-5.6 mL/min/1.73 m²) than placebo (-2.7 mL/min/1.73 m²), but values approached baseline after washout.
The study concluded that finerenone significantly reduces albuminuria in type 1 diabetes patients with CKD, supporting its potential therapeutic benefit.

Hasty Briefsbeta